Full Protocol Guide

Semax 30mg

A research-use ACTH-fragment peptide entry for neuropeptide literature context and safety review.

Semax 30mg product vial
Semax 30mg vial Beauty, Wellness & Lifestyle
ProductSemax 30mg
CategoryBeauty, Wellness & Lifestyle
FormatSemax 30mg vial
ReviewSource-linked guide

Contents

Use this guide as a structured review page. The same headings appear for every protocol so clients and the care team can scan the page consistently.

Quickstart Highlights

Semax is a synthetic heptapeptide analog of ACTH(4–10) developed in Russia and studied primarily for cognitive enhancement and neuroprotection[1][2]. While intranasal administration is most common in clinical literature, subcutaneous injection offers a convenient once‑daily alternative for research purposes[1][4]. This educational protocol presents a practical SC approach using straightforward reconstitution for accurate insulin‑syringe measurements.

  • Reconstitute: Add 3.0 mL bacteriostatic water (max vial capacity) → ~3.33 mg/mL concentration.
  • Typical daily range: 300–800 mcg once daily (gradual titration recommended).
  • Easy measuring: At 3.33 mg/mL, 1 unit = 0.01 mL ≈ 33.3 mcg on a U‑100 insulin syringe.
  • Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles[2][9]. Open source

Dosing & Reconstitution Guide

Educational guide for reconstitution and weekly dosing

Standard / Gradual Approach (3 mL = ~3.33 mg/mL)
Week Daily Dose (mcg) Units (per injection) (mL)
Weeks 1–2 300 mcg 9 units (0.09 mL)
Weeks 3–4 500 mcg 15 units (0.15 mL)
Weeks 5–6 600 mcg 18 units (0.18 mL)
Weeks 7–8 800 mcg 24 units (0.24 mL)
  • For ≤10‑unit (≤0.10 mL) administrations, consider 30‑ or 50‑unit insulin syringes for improved readability.
  • Frequency: Inject once daily subcutaneously[1][4]. This schedule uses the largest practical dilution (3.0 mL) to ensure per‑injection volumes are accurate and manageable. Most human nootropic studies use intranasal dosing in the range of 400–900 mcg/day divided into multiple administrations[2][3]; this SC protocol delivers comparable total daily amounts in a single injection for convenience.

Reconstitution Steps

Reference-derived details for Semax 30mg.

  • Draw 3.0 mL bacteriostatic water with a sterile syringe.
  • Inject slowly down the vial wall; avoid foaming.
  • Gently swirl/roll until dissolved (do not shake vigorously).
  • Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light[2]. Open source

Supplies Needed

Plan based on an 8–16 week daily protocol with gradual titration.

  • Peptide Vials (Semax, 10 mg each):
  • Peptide Vials (Semax, 10 mg each):: 8 weeks ≈ 4 vials
  • Peptide Vials (Semax, 10 mg each):: 12 weeks ≈ 6 vials
  • Peptide Vials (Semax, 10 mg each):: 16 weeks ≈ 8 vials
  • Insulin Syringes (U‑100):
  • Insulin Syringes (U‑100):: Per week: 7 syringes (1/day)
  • Insulin Syringes (U‑100):: 8 weeks: 56 syringes
  • Insulin Syringes (U‑100):: 12 weeks: 84 syringes
  • Insulin Syringes (U‑100):: 16 weeks: 112 syringes
  • Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
  • Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.: 8 weeks (4 vials): 12 mL → 2 × 10 mL bottles
  • Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.: 12 weeks (6 vials): 18 mL → 2 × 10 mL bottles
  • Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.: 16 weeks (8 vials): 24 mL → 3 × 10 mL bottles
  • Alcohol Swabs: One for the vial stopper + one for the injection site each day.
  • Alcohol Swabs: One for the vial stopper + one for the injection site each day.: Per week: 14 swabs (2/day)
  • Alcohol Swabs: One for the vial stopper + one for the injection site each day.: 8 weeks: 112 swabs → recommend 2 × 100‑count boxes
  • Alcohol Swabs: One for the vial stopper + one for the injection site each day.: 12 weeks: 168 swabs → recommend 2 × 100‑count boxes
  • Alcohol Swabs: One for the vial stopper + one for the injection site each day.: 16 weeks: 224 swabs → recommend 3 × 100‑count boxes

Protocol Overview

Concise summary of the once‑daily SC regimen.

  • Goal: Support cognitive function, attention, and neuroprotective pathways studied in clinical literature[2][5]. Open source
  • Schedule: Daily subcutaneous injections for 8 weeks (extend to 12–16 weeks with cycling if desired)[4]. Open source
  • Dose Range: 300–800 mcg daily with gradual titration; aligns with typical human nootropic dosing ranges[2][3]. Open source
  • Reconstitution: 3.0 mL per 10 mg vial (~3.33 mg/mL) for accurate unit measurements.
  • Storage: Lyophilized frozen; reconstituted refrigerated; use within 30 days[2][9]. Open source

Dosing Protocol

Suggested daily titration approach.

  • Start: 300 mcg daily; increase by ~100–200 mcg every 1–2 weeks as tolerated.
  • Target: 600–800 mcg daily by Weeks 5–8; adjust based on individual response.
  • Frequency: Once per day (subcutaneous)[1][4]. Open source
  • Cycle Length: 8 weeks continuous; optional extension to 12–16 weeks with off‑periods (e.g., 6 weeks on, 2 weeks off)[4]. Open source
  • Timing: Any consistent time; rotate injection sites systematically.

Storage Instructions

Proper storage preserves peptide quality.

  • Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions[9]; minimize moisture exposure. Open source
  • Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); stable for up to 30 days[2][9]; avoid freeze–thaw cycles. Open source
  • Allow vials to reach room temperature before opening to reduce condensation uptake.
  • Protect from light; wrap vials in foil or store in an opaque container[9]. Open source

Important Notes

Practical considerations for consistency and safety.

  • Use new sterile insulin syringes for each injection; dispose in a sharps container[7]. Open source
  • Rotate injection sites (abdomen, thighs, upper arms) at least 1–2 inches from previous sites to reduce local irritation[7]. Open source
  • Inject slowly; wait a few seconds before withdrawing the needle.
  • Document daily dose, injection time, and site rotation to maintain consistency.
  • Most human data are for 4–8 weeks of continuous use; longer protocols should incorporate rest periods[4]. Open source

How This Works

Semax is a synthetic analog of the ACTH(4–10) fragment with a C‑terminal Pro‑Gly‑Pro tripeptide extension that enhances metabolic stability[1][5]. Clinical and preclinical literature suggest it modulates brain‑derived neurotrophic factor (BDNF) expression, enhances cholinergic and dopaminergic neurotransmission, and exhibits neuroprotective properties in models of cerebrovascular and cognitive impairment[2][5]. Human studies in Russia have employed Semax for cognitive support in conditions ranging from mild cognitive impairment to acute stroke recovery, typically using intranasal administration[2][3][6]. Subcutaneous delivery offers an alternative route with potentially more sustained systemic absorption[1][4]

Lifestyle Factors

Complementary strategies for optimal cognitive support.

  • Maintain consistent sleep schedules and prioritize 7–9 hours of quality sleep per night.
  • Engage in regular aerobic exercise and cognitive training to reinforce neuroplastic adaptations.
  • Follow a balanced diet rich in omega‑3 fatty acids, antioxidants, and micronutrients that support brain health.
  • Manage stress through mindfulness, meditation, or other relaxation techniques.
  • Stay mentally active with challenging tasks, learning new skills, and social engagement.

Potential Benefits & Side Effects

Observations from preclinical and clinical literature.

  • May support attention, memory consolidation, and learning in clinical populations with cognitive deficits[2][5]. Open source
  • Studied in neurological conditions including stroke, traumatic brain injury, and optic neuropathy with favorable safety profiles in month‑long human trials[2][3][6]. Open source
  • Generally well tolerated; intranasal administration may cause minor nasal irritation; subcutaneous injection may produce mild injection‑site reactions (redness, itching).
  • No significant elevations in cortisol or other adverse endocrine effects reported in clinical studies[2]. Open source
  • Effects are dose‑dependent; titration helps identify the minimum effective dose for individual response[2]. Open source

Injection Technique

General subcutaneous guidance from clinical best‑practice resources[7][8][9].

  • Clean the vial stopper and injection site with alcohol swabs; allow to dry completely.
  • Pinch a 1–2 inch skinfold; insert the needle at 45–90° into subcutaneous tissue (angle depends on needle length and fat layer)[7]. Open source
  • Do not aspirate for subcutaneous injections; inject slowly and steadily[7][8]. Open source
  • Withdraw the needle at the same angle; apply gentle pressure with clean gauze (do not rub vigorously)[7]. Open source
  • Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy or tissue irritation; maintain at least 1–2 inches between injection sites[7]. Open source
  • Dispose of used syringes immediately in a proper sharps container[7]. Open source

Important Note

This page is informational and does not authorize use. Peptify clients should complete assessment, disclose medications and health history, and follow the clinician-approved plan only.

  • Do not start, stop, combine, or change a protocol based only on website content.
  • Emergency symptoms require urgent medical care, not a website or routine follow-up message.

References

Reference-derived details for Semax 30mg.

  • Semax (10mg Vial) Open source
  • Neuroscience and Behavioral Physiology (Springer) — Comparative study of Semax administration routes (intranasal vs. subcutaneous) in animal models View Source Open source
  • Vidal Drug Reference (Russia) — Official prescribing information for Semax 0.1% intranasal drops; human dosing guidelines and administration schedules View Source Open source
  • Journal of Neurology and Psychiatry (Russia) — Clinical trial of Semax in ischemic stroke patients (6,000 mcg/day intranasal protocol with cycling) View Source Open source
  • Peptides.org — Semax dosage overview, cycling recommendations, and protocol duration guidance View Source Open source
  • Journal of Higher Nervous Activity (Russia) — Early human study introducing Semax’s nootropic properties and mechanism of action View Source Open source
  • Vestnik Oftalmologii (Russian Ophthalmology Journal) — Human study of Semax in glaucomatous optic neuropathy; 30‑day safety data View Source Open source
  • Johns Hopkins Arthritis Center — Clinical guide to subcutaneous injection technique (preparation, angle, site rotation) View Source Open source
  • CDC — Vaccine administration guidelines for subcutaneous injections (angle, no aspiration) View Source Open source
  • Pharmaceutics (MDPI) — Overview of Russian peptide drugs including Semax; formulation stability and storage considerations View Source Open source
  • Drug Testing and Analysis (Wiley) — Review of nootropic peptides including Semax; discussion of human intranasal use patterns View Source Open source
  • Prime Lab Peptides — Semax (10 mg) product page; quality specifications and batch documentation View Source